dsm-firmenich launches ModulaSENSE® Bitter – a novel taste modulation technology to enhance drug palatability

dsm-firmenich – a leading innovator in nutrition, health, and beauty – announces the launch of a new technology, ModulaSENSE® Bitter, designed to help pharmaceutical companies improve the taste of drugs and increase patient adherence. This new technology addresses the growing challenge of bitterness in active pharmaceutical ingredients (APIs), helping drug formulators to create more patient-friendly oral medicines.

ModulaSENSE® Bitter is designed to tackle the challenge of poor taste in drug formulations, which remains a significant issue, with more than 60% of APIs considered intrinsically bitter. The novel technology addresses these challenges through proprietary receptor-based methods and expert sensory validation, providing formulators with novel insights into how compounds interact with bitter taste receptors to guide formulation-specific bitterness management strategies.

ModulaSENSE® Bitter combines bitter blockers, maskers, and sweeteners with evidence-based insights from dsm-firmenich’s trained sensory panels to improve overall flavor balance. It can be applied across a wide range of oral dosage forms – including solid, liquid, and semi-solid formulations – and each solution is accompanied by structured sensory evaluation and a comprehensive technical documentation and regulatory package.